Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 13

1.

Making technological innovation work for sustainable development.

Anadon LD, Chan G, Harley AG, Matus K, Moon S, Murthy SL, Clark WC.

Proc Natl Acad Sci U S A. 2016 Aug 30;113(35):9682-90. doi: 10.1073/pnas.1525004113. Epub 2016 Aug 12.

PMID:
27519800
2.

Assessing the health impact of transnational corporations: its importance and a framework.

Baum FE, Sanders DM, Fisher M, Anaf J, Freudenberg N, Friel S, Labonté R, London L, Monteiro C, Scott-Samuel A, Sen A.

Global Health. 2016 Jun 15;12(1):27. doi: 10.1186/s12992-016-0164-x.

3.

Delinking Investment in Antibiotic Research and Development from Sales Revenues: The Challenges of Transforming a Promising Idea into Reality.

Outterson K, Gopinathan U, Clift C, So AD, Morel CM, Røttingen JA.

PLoS Med. 2016 Jun 14;13(6):e1002043. doi: 10.1371/journal.pmed.1002043. eCollection 2016 Jun.

4.

Prices, Costs, and Affordability of New Medicines for Hepatitis C in 30 Countries: An Economic Analysis.

Iyengar S, Tay-Teo K, Vogler S, Beyer P, Wiktor S, de Joncheere K, Hill S.

PLoS Med. 2016 May 31;13(5):e1002032. doi: 10.1371/journal.pmed.1002032. eCollection 2016 May.

5.

Target prices for mass production of tyrosine kinase inhibitors for global cancer treatment.

Hill A, Gotham D, Fortunak J, Meldrum J, Erbacher I, Martin M, Shoman H, Levi J, Powderly WG, Bower M.

BMJ Open. 2016 Jan 27;6(1):e009586. doi: 10.1136/bmjopen-2015-009586.

6.

Efficacy and HIV drug resistance profile of second-line ART among patients having received long-term first-line regimens in rural China.

Wang J, Wang Z, Liu J, Yue Y, Yang S, Huang H, He C, Liao L, Xing H, Ruan Y, Shao Y.

Sci Rep. 2015 Oct 8;5:14823. doi: 10.1038/srep14823.

7.

Bibliographic review of research publications on access to and use of medicines in low-income and middle-income countries in the Eastern Mediterranean Region: identifying the research gaps.

Rashidian A, Jahanmehr N, Jabbour S, Zaidi S, Soleymani F, Bigdeli M.

BMJ Open. 2013 Oct 3;3(10):e003332. doi: 10.1136/bmjopen-2013-003332.

8.

Access to drugs for treatment of noncommunicable diseases.

Bollyky TJ.

PLoS Med. 2013;10(7):e1001485. doi: 10.1371/journal.pmed.1001485. Epub 2013 Jul 23. No abstract available.

9.
10.

Patent and exclusivity status of essential medicines for non-communicable disease.

Mackey TK, Liang BA.

PLoS One. 2012;7(11):e51022. doi: 10.1371/journal.pone.0051022. Epub 2012 Nov 30.

11.

Innovation and access to medicines for neglected populations: could a treaty address a broken pharmaceutical R&D system?

Moon S, Bermudez J, 't Hoen E.

PLoS Med. 2012;9(5):e1001218. doi: 10.1371/journal.pmed.1001218. Epub 2012 May 15. No abstract available.

12.

'Getting to zero': a steep path ahead.

Satyanarayana K.

Indian J Med Res. 2011 Dec;134(6):742-5. doi: 10.4103/0971-5916.92621. No abstract available.

13.

CMV retinitis in China and SE Asia: the way forward.

Heiden D, Saranchuk P.

BMC Infect Dis. 2011 Nov 24;11:327. doi: 10.1186/1471-2334-11-327.

Items per page

Supplemental Content

Write to the Help Desk